MilliporeSigma

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany,  delivers expertise and innovation in cell and gene therapy development and manufacturing, enabling clients to advance life-changing therapies from early development through commercialization.

With over 30 years of experience in viral vectors, our experts collaborate with leading pharmaceutical and biotechnology companies to provide development and manufacturing support for lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vectors.

MilliporeSigma’s viral vector CDMO state-of-the-art facility in Carlsbad, CA offers end-to-end capabilities, including process and analytical development, suspension and adherent GMP production, fill/finish, and on-site product testing and regulatory support. We leverage optimized solutions such as lentiviral vector and AAV platforms to deliver reliable, high-quality viral vectors.

Let`s accelerate your viral vector-based therapies, reduce risk, and bring life-changing treatments to patients faster.